Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Definitive Healthcare Corp T.DH.R


Primary Symbol: DH

Definitive Healthcare Corp. is engaged in transforming data, analytics, and expertise into healthcare commercial intelligence. The Company’s solutions are designed to provide information on healthcare providers and their activities to help its customers optimize everything from product development to go-to-market planning and sales and marketing execution. Its software-as-a-service (SaaS) platform uses deep analytics and data science to help customers develop data-driven strategic decisions, such as finding new markets to enter, building comprehensive go-to-market strategies, accessing tactical information to help target the right decision makers and improving win rates with detailed contextual information. It transforms data into intelligence through artificial intelligence (AI) and machine learning (ML) algorithms that ingest, cleanse, link, and analyze the data to create new intelligence and analytics. All of its business is conducted through AIDH TopCo, LLC (Definitive OpCo).


NDAQ:DH - Post by User

Post by retiredcfon Oct 26, 2016 3:20pm
724 Views
Post# 25389211

RBC

RBCThis was written early this morning. The interesting part is that their downside scenario target was $20.00 meaning that even in a worst case scenario, in no way did they see this news resulting in a 45% haircut. Thus we have, as some of us believe, a significant overreaction, notwithstanding comments from the shorters who are now beginning to arrive on this BB. GLTA

October 26, 2016

DH Corporation

Downgrading to Sector Perform; Q3/16 miss and outlook weaker than expected

Our view: Q3/16 EPS missed consensus by 20% and reduced guidance for the second consecutive quarter suggests that fundamentals are materially weaker than we expected. Low earnings visibility and the absence of a near-term catalyst are likely to limit significant valuation upside. We had hoped that DH’s fundamentals would gradually improve with evidence of stronger growth in 2017. This appears unlikely and we downgrade to Sector Perform.

Key points:

Disappointing Q3/16 on multiple fronts: (1) EPS of $0.49 vs. RBC at $0.56 and $0.61 consensus [range of $0.55–0.66]; (2) revised guidance which appears reduced from before; (3) although Canada/U.S. lending solutions revenues were in line, Canadian payments, GTBS, and U.S. integrated core missed and consolidated EBITDA margins were 320bps below our forecast; (4) first real evidence that Canadian cheque revenues are declining, with estimating the rate of decline likely to be a greater focal point for investors; and (5) GTBS results disappointed again.

Downgrading to Sector Perform (from Outperform); reducing 12-month price target to $26 (from $48). The reduced target reflects both lower financial forecasts and a lower target P/E multiple (was 15.5x, now 11.5x, which is where DH traded prior to Q3/16 earnings being released). DH trades at a significant valuation discount to U.S. peers, but we think valuation multiple expansion is unlikely in the near term given a more cautious outlook.

We think DH has become a “show me” story. Shares have potentially substantial upside, but early signs of a catalyst are needed. Earnings releases/outlook disappointed in the last three quarters. DH’s share price is down ~30% in the past year and the stock trades at a significant discount to U.S. peers, so we think the share price already reflected some growth concerns. We think early and sustainable signs of significant improvement in most of DH’s segments (particularly GTBS and U.S. lending solutions) are key to getting the stock going again.

The dividend conundrum. We believe DH is still significantly owned by retail investors, who we think understand the company’s repositioning from a lower-growth high-yielding income trust to a higher-growth FinTech story but still enjoy the nice dividend yield. Given the significant share price decline and U.S. peers with a nominal or no dividend yield, we believe it may be worth considering a dividend reduction to buy back stock and/or de-lever (a 1.5% dividend yield could allow de-levering of ~0.2x EBITDA annually), which would likely be negative for the share price initially but may be beneficial longer-term. Our forecasts assume no change to the dividend 


<< Previous
Bullboard Posts
Next >>